P2, N=184, Recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: Dec 2026 --> Nov 2027 | Trial primary completion date: Dec 2026 --> Nov 2027
9 months ago
Trial completion date • Trial primary completion date • Metastases
Based on this finding, KORTUC with external irradiation is considered to be an optimal treatment strategy for patients with newly diagnosed LRCC this disease. Additionally, KORTUC may be an effective radiation response enhancer in multiple cancer types in which locoregional control after RT alone remains poor.
Indeed, H2O2 has been clinically developed as a radiosensitizer (development code: KRC-01)... Intratumoral H2O2 administration enhanced the abscopal effect through activating antitumor immunity by RT.